All Stories

  1. Data from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  2. Figure S1 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  3. Figure S10 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  4. Figure S11 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  5. Figure S12 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  6. Figure S13 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  7. Figure S14 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  8. Figure S15 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  9. Figure S16 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  10. Figure S2 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  11. Figure S3 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  12. Figure S4 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  13. Figure S5 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  14. Figure S6 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  15. Figure S7 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  16. Figure S8 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  17. Figure S9 from Depleting IL1R2<sup>+</sup> Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  18. Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD1 Immunotherapy

    Article • Cancer Research, September 2025, American Association for Cancer Research (AACR)

    Dr. Guillaume E. Courtoy

  19. Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer

    Article • Proceedings of the National Academy of Sciences, December 2024, Proceedings of the National Academy of Sciences

    Dr. Guillaume E. Courtoy

  20. Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies

    Article • Endocrines, February 2024, MDPI AG

    Dr. Guillaume E. Courtoy

  21. Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies

    Article • January 2024, MDPI AG

    Dr. Guillaume E. Courtoy

  22. Dietary supplementation of cystinotic mice by lysine inhibits the megalin pathway and decreases kidney cystine content

    Article • Scientific Reports, October 2023, Springer Science + Business Media

    Dr. Guillaume E. Courtoy

  23. Reviewers of the Year 2022: F&S Science celebrates excellence in our world class reviewers

    Article • F&S Science, August 2023, Elsevier

    Dr. Guillaume E. Courtoy

  24. Quantification of lung fibrosis in COVID-19 related and -unrelated ARDS

    Article • Revue des Maladies Respiratoires, February 2023, Elsevier

    Dr. Guillaume E. Courtoy

  25. Cover Image, Volume 59, Issue 7‐8

    Article • genesis, August 2021, Wiley

    Dr. Guillaume E. Courtoy

  26. Semi‐automated digital quantification of cellular infiltrates for in vivo evaluation of transplanted islets of Langerhans encapsulated with bioactive materials

    Article • Xenotransplantation, July 2021, Wiley

    Dr. Guillaume E. Courtoy

  27. Generation and characterization of a tamoxifen‐inducible Vsx1‐CreERT2 line to target V2 interneurons in the mouse developing spinal cord

    Article • genesis, May 2021, Wiley

    Dr. Guillaume E. Courtoy

  28. Digital Image Analysis of Picrosirius Red Staining: A Robust Method for Multi-Organ Fibrosis Quantification and Characterization

    Article • Biomolecules, November 2020, MDPI AG

    Dr. Guillaume E. Courtoy

  29. Adipose tissue–derived stem cells protect the primordial follicle pool from both direct follicle death and abnormal activation after ovarian tissue transplantation

    Article • Journal of Assisted Reproduction and Genetics, November 2020, Springer Science + Business Media

    Dr. Guillaume E. Courtoy

  30. Canagliflozin protects the vascular barrier during sepsis by AMPK dependant mechanisms

    Article • Archives of Cardiovascular Diseases Supplements, October 2020, Elsevier

    Dr. Guillaume E. Courtoy

  31. α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway

    Article • International Journal of Molecular Sciences, August 2020, MDPI AG

    Dr. Guillaume E. Courtoy

  32. Accurate and live peroxisome biogenesis evaluation achieved by lentiviral expression of a green fluorescent protein fused to a peroxisome targeting signal 1

    Article • Histochemistry and Cell Biology, March 2020, Springer Science + Business Media

    Dr. Guillaume E. Courtoy

  33. Fibroid management in premenopausal women

    Article • Climacteric, January 2019, Taylor & Francis

    Dr. Guillaume E. Courtoy

  34. Molecular mechanisms responsible for myoma volume reduction after ulipristal acetate

    Article • Fertility and Sterility, September 2018, Elsevier

    Dr. Guillaume E. Courtoy

  35. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review

    Article • Reproductive BioMedicine Online, August 2018, Elsevier

    Dr. Guillaume E. Courtoy

  36. Gene expression changes in uterine myomas in response to ulipristal acetate treatment

    Article • Reproductive BioMedicine Online, August 2018, Elsevier

    Dr. Guillaume E. Courtoy

  37. Matrix Metalloproteinase Activity Correlates With Uterine Myoma Volume Reduction After Ulipristal Acetate Treatment

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2018, Endocrine Society

    Dr. Guillaume E. Courtoy

  38. Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation

    Article • Gynecologic and Obstetric Investigation, December 2017, Karger Publishers

    Dr. Guillaume E. Courtoy

  39. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment

    Article • Fertility and Sterility, August 2015, Elsevier

    Dr. Guillaume E. Courtoy